Evidence map›Paper›PMID 37632557›Full record

ArticleWorld journal of urology2023

Experts' recommendations in laser use for the endoscopic treatment of prostate hypertrophy: a comprehensive guide by the European Section of Uro-Technology (ESUT) and Training-Research in Urological Surgery and Technology (T.R.U.S.T.)-Group.

Gernot Ortner, Selcuk Güven, Bhaskar Kumar Somani, Andre Nicklas, Cesare Marco Scoffone, Cecilia Gracco, Ioannis Kartalas Goumas, Thorsten Bach, Fernando Gómez Sancha, Felipe C A Figueredo and 19 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Gernot OrtnerDepartment of Urology and Andrology, General Hospital Hall i.T., Hall in Tirol, Austria. gerni_o@hotmail.com.ORCID http://orcid.org/0000-0002-2454-6599
Selcuk GüvenDepartment of Urology, Meram School of Medicine, Necmettin Erbakan University, Konya, Turkey.
Bhaskar Kumar SomaniDepartment of Urology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Andre NicklasDepartment of Urology and Andrology, General Hospital Hall i.T., Hall in Tirol, Austria.
Cesare Marco ScoffoneDepartment of Urology, Cottolengo Hospital of Torino, Turin, Italy.
Cecilia GraccoDepartment of Urology, Cottolengo Hospital of Torino, Turin, Italy.
Ioannis Kartalas GoumasDepartment of Urology, Istituto Clinico Beato Matteo, Vigevano, Italy.
Thorsten BachDepartment of Urology, Asklepios Westklinikum Rissen, Hamburg, Germany.
Fernando Gómez SanchaDepartment of Urology, ICUA-Clínica CEMTRO, Madrid, Spain.
Felipe C A FigueredoInstituto da Próstata Aumentada, Hospital Pompéia, Caxias do Sul, Brazil.
Amy KrambeckDepartment of Urology, Northwestern Medicine, Chicago, IL, USA.
Giorgio BozziniDepartment of Urology, ASST Lariana, Como, Italy.
Karin LehrichDepartment of Urology, Urological Laser Center, Vivantes Auguste-Viktoria-Hospital Berlin, Berlin, Germany.
Evangelos LiatsikosDepartment of Urology, University of Patras, Patras, Greece.
Panagiotis KallidonisDepartment of Urology, University of Patras, Patras, Greece.
Jean Baptiste RocheDepartment of Urology, Clinique Saint-Augustin, Bordeaux, France.
Arkadiusz MiernikDepartment of Urology, University of Freiburg, Freiburg, Germany.
Dmitry EnikeevDepartment of Urology, Medical University of Vienna, Vienna, Austria.
Lutfi TuncDepartment of Urology, Acibadem Hospital, Ankara, Turkey.
Naeem BhojaniDivision of Urology, Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montreal, QC, Canada.
Peter GillingDepartment of Urology, Tauranga Hospital, University of Auckland, Auckland, New Zealand.
Javier Romero OteroROC Clinic and HM Urological Department, Fundación Investigación HM Hospitales, HM Hospitales, Madrid, Spain.
Angelo PorrecaDepartment of Oncological Urology, Veneto Institute of Oncology (IOV)-IRCCS, Padua, Italy.
Sasha AhyaiDepartment of Urology, Medical University of Graz, Graz, Austria.
Christopher NetschDepartment of Urology, Asklepios Klinik Barmbek, Hamburg, Germany.
Ali Serdar GözenDepartment of Urology, Medius Kliniken, Ruit, Baden-Württemberg, Germany.
Udo NageleDepartment of Urology and Andrology, General Hospital Hall i.T., Hall in Tirol, Austria.
Thomas R W HerrmannTraining and Research in Urological Surgery and Technology (T.R.U.S.T.)-Group, Hall in Tirol, Austria.
Theodoros TokasTraining and Research in Urological Surgery and Technology (T.R.U.S.T.)-Group, Hall in Tirol, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo identify expert laser settings for BPH treatment and evaluate the application of preventive measures to reduce complications.

methodsA survey was conducted after narrative literature research to identify relevant questions regarding laser use for BPH treatment (59 questions). Experts were asked for laser settings during specific clinical scenarios. Settings were compared for the reported laser types, and common settings and preventive measures were identified.

resultsTwenty-two experts completed the survey with a mean filling time of 12.9 min. Ho:YAG, Thulium fiber laser (TFL), continuous wave (cw) Tm:YAG, pulsed Tm:YAG and Greenlight™ lasers are used by 73% (16/22), 50% (11/22), 23% (5/22), 13.6% (3/22) and 9.1% (2/22) of experts, respectively. All experts use anatomical enucleation of the prostate (EEP), preferentially in one- or two-lobe technique. Laser settings differ significantly between laser types, with median laser power for apical/main gland EEP of 75/94 W, 60/60 W, 100/100 W, 100/100 W, and 80/80 W for Ho:YAG, TFL, cwTm:YAG, pulsed Tm:YAG and Greenlight™ lasers, respectively (p = 0.02 and p = 0.005). However, power settings within the same laser source are similar. Pulse shapes for main gland EEP significantly differ between lasers with long and pulse shape modified (e.g., Moses, Virtual Basket) modes preferred for Ho:YAG and short pulse modes for TFL (p = 0.031).

conclusionHo:YAG lasers no longer seem to be the mainstay of EEP. TFL lasers are generally used in pulsed mode though clinical applicability for quasi-continuous settings has recently been demonstrated. One and two-lobe techniques are beneficial regarding operative time and are used by most experts.

Indexed as

Lasers, Solid-StateLaser TherapyLithotripsy, LaserProstatic HyperplasiaHumansHypertrophyMaleProstateThuliumThuliumLaserProstat* hyperplasiaProstat* hypertrophySettingsSurvey

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.